Kallyope has rebranded as TriGemX Bio and raised $94 million to advance a migraine pipeline that focuses on a Phase 3 program carried forward after a corporate restructuring. The funding is intended to support late-stage development tied to the company’s former Tanabe Pharma asset, now positioned under the TriGemX umbrella. The rebrand underscores a strategic shift from broader neuro/brain-health positioning to a narrower migraine focus—an increasingly common playbook for development-stage biotechs seeking investor clarity around clinical milestones. From a sector standpoint, the financing highlights continued appetite for migraine therapeutics, particularly those with fast time-to-data expectations once Phase 3 programs are underway. Near-term milestones will center on Phase 3 execution, readout timing, and the ability to manage safety/tolerability as efficacy signals mature.